01:49 PM EDT, 09/13/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Friday that the US Food and Drug Administration approved Dupixent as a supplementary maintenance treatment for inadequately controlled chronic rhinosinusitis with nasal polyps in adolescents, a chronic nasal disease.

Dupixent's approval is supported by trials showing reduced nasal congestion, polyp size and need for corticosteroids or surgery, and improved safety and pharmacokinetic data in adults and adolescents with asthma and CRSwNP.

The treatment is now available for adolescent patients as young as 12 years.

Price: 1154.80, Change: -9.66, Percent Change: -0.83